Eiger Biopharmaceuticals, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$374Kgeneral payments (2019-2025)
$11Kresearch payments (2019-2025)
38clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2021 $100K
2022 $88K
2023 $186K

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Cardiovascular Disease $199K
Pediatrics $149K
Endocrinology, Diabetes & Metabolism $24K
Gastroenterology (Internal Medicine) $964
Hepatology $827
Family Medicine $72.60

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Evan Loh Merion Station, PA Cardiovascular Disease $199,000.00
David Apelian Boonton, NJ Pediatrics $148,722.84
Tracey Mclaughlin Stanford, CA Endocrinology, Diabetes & Metabolism $24,333.83
Jeffrey Glenn Stanford, CA Gastroenterology (Internal Medicine) $732.78
Robert Gish Folsom, CA Hepatology $722.69
Pierre Gholam Cleveland, OH Gastroenterology (Internal Medicine) $104.17
Tatyana Kushner New York, NY Hepatology $104.16
Kris Kowdley Seattle, WA Gastroenterology (Internal Medicine) $76.94
Marilyn Tan Stanford, CA Endocrinology, Diabetes & Metabolism $60.72
Helen Adams New York, NY Medical $55.00

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.